<DOC>
	<DOCNO>NCT00429065</DOCNO>
	<brief_summary>The purpose study determine whether specific subtype lymphoma respond optimally treatment rituximab chemotherapy .</brief_summary>
	<brief_title>Treatment Good Prognosis , BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R Patients &lt; 61 Years Old .</brief_title>
	<detailed_description>Treatment rituximab chemotherapy ( R-CHOP ) accept treatment young patient diffuse large B cell Non-Hodgkin 's Lymphoma . However every patient benefit expensive therapy . Recent data suggest patient BCL-6 negative lymphoma sensitive Rituximab therapy . It also know patient high-intermediate high IPI risk benefit form standard three weekly CHOP chemotherapy . In study intend define subgroup patient therapy maximum benefit . We prospectively treat group patient follow characteristic : &lt; 60 year old low low intermediate IPI risk BCL-6 negative B-cell NHL Treatment regimen : R-CHOP ( standard dosis ) 8 cycle</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Diagnosis Large B cell NonHodgkin Lymphoma CD20+ BCL6 negative Age &lt; 61 year old ECOG 2 less IPI low , low intermediate Stage II , III IV Signed Informed Consent Stage I Previous treatment Lymphomatous central nervous system involvement Heart disease Kidney failure ( serum creatinine &gt; 2 mg/dl ) HIV + Viral Hepatitis Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Non-Hodgkin lymphoma</keyword>
	<keyword>rituximab</keyword>
	<keyword>immunotherapy</keyword>
</DOC>